News list for "orforglipron"

Eli Lilly (LLY. N) announced the results of a second obesity trial on Orforglipron, a drug that reduced weight by 9.6 percent in obese and diabetic patients. It plans to apply for approval of the diet drug in 2025.

orforglipron 2025

2025-08-26 10:47:44

礼来(LLY.N)公布关于Orforglipron的第二项肥胖试验结果，药物使肥胖和糖尿病患者的体重减轻了9.6%，计划在2025年申请减肥药的批准。

orforglipron 2025

礼来(LLY.N)公布关于Orforglipron的第二项肥胖试验结果，药物使肥胖和糖尿病患者的体重减轻了9.6%，计划在2025年申请减肥药的批准。

2025-08-26 10:47:44

Lilly (LLY. N) U.S. stocks widened their premarket decline to 11 percent after experiments showed that Lilly's oral drug Orforglipron lost an average of 11.2 percent in weight.

orforglipron 11.2

Lilly (LLY. N) U.S. stocks widened their premarket decline to 11 percent after experiments showed that Lilly's oral drug Orforglipron lost an average of 11.2 percent in weight.

2025-08-07 10:31:30

礼来(LLY.N)美股盘前跌幅扩大至11%，实验显示，礼来口服药物Orforglipron平均减重11.2%。

orforglipron 11.2

礼来(LLY.N)美股盘前跌幅扩大至11%，实验显示，礼来口服药物Orforglipron平均减重11.2%。

2025-08-07 10:31:30

Disclaimer:

1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.

2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.

News list for "orforglipron"

7x24 Crypto Flash News

Hot News

Related Recommendations